Purpose: Differentiating prostate cancer (PCa) in the transition zone (TZ) from benign prostate hyperplasia based on MRI findings has often been challenging. This study aims to evaluate the utility of a quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using time-resolved angiography with stochastic trajectories‒volumetric interpolated breath-hold examination (TWIST-VIBE) in cases of PCa in the TZ.
Methods: In this retrospective study, we examined the biopsy findings of 23 patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL) who underwent DCE-MRI using TWIST-VIBE. The parameters analyzed included Ktrans (the transfer constant), Kep (the reflux constant), Ve (the extravascular extracellular volume fraction), and the initial area under the curve on the Tissue 4D platform (Siemens).
Results: The quantitative analysis revealed no significant differences in any of the examined parameters between positive and negative PCa in the TZ. Additionally, there were no significant differences among the histological grades of PCa in the TZ.
Conclusion: A quantitative analysis of findings obtained by DCE-MRI using TWIST-VIBE did not yield statistically significant results for differentiating the status of PCa in the TZ. However, DCE-MRI using TWIST-VIBE, an ultrafast DCE-MRI technique, may be useful for evaluating tumor hemodynamics and assessing the size dependence of prostate cancer lesions in the transition zone.
{"title":"Quantitative analysis of dynamic-contrast MRI for the assessment of prostate cancer in the transition zone.","authors":"Mariko Doai, Tamaki Kondo, Yuka Nishino, Ippei Chikazawa, Sohsuke Yamada, Keiya Hirata, Katsuhito Miyazawa","doi":"10.1177/03915603251414596","DOIUrl":"https://doi.org/10.1177/03915603251414596","url":null,"abstract":"<p><strong>Purpose: </strong>Differentiating prostate cancer (PCa) in the transition zone (TZ) from benign prostate hyperplasia based on MRI findings has often been challenging. This study aims to evaluate the utility of a quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using time-resolved angiography with stochastic trajectories‒volumetric interpolated breath-hold examination (TWIST-VIBE) in cases of PCa in the TZ.</p><p><strong>Methods: </strong>In this retrospective study, we examined the biopsy findings of 23 patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL) who underwent DCE-MRI using TWIST-VIBE. The parameters analyzed included K<sup>trans</sup> (the transfer constant), K<sup>ep</sup> (the reflux constant), Ve (the extravascular extracellular volume fraction), and the initial area under the curve on the Tissue 4D platform (Siemens).</p><p><strong>Results: </strong>The quantitative analysis revealed no significant differences in any of the examined parameters between positive and negative PCa in the TZ. Additionally, there were no significant differences among the histological grades of PCa in the TZ.</p><p><strong>Conclusion: </strong>A quantitative analysis of findings obtained by DCE-MRI using TWIST-VIBE did not yield statistically significant results for differentiating the status of PCa in the TZ. However, DCE-MRI using TWIST-VIBE, an ultrafast DCE-MRI technique, may be useful for evaluating tumor hemodynamics and assessing the size dependence of prostate cancer lesions in the transition zone.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251414596"},"PeriodicalIF":0.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1177/03915603251412607
Lucas J Cortés, Germán Olaya, José S Cortés, Juan I Caicedo, Jorge A Flórez
Background: Prostate cancer is the most common solid neoplasm in men, with an increasing incidence. This study describes clinical and sociodemographic features and PSA levels, and evaluate their associations with stage, risk categories, metastasis, and mortality in a public tertiary hospital in southern Colombia.
Methodology: The present retrospective cohort study included 590 patients diagnosed with prostate cancer between 2020 and 2023. Sociodemographic and clinical variables, PSA levels, pathological characteristics and risk scales were analyzed. Patients were categorized into two groups: living (n = 429) and deceased by prostate cancer (n = 109), and other causes (n = 44). Statistical analyses were performed to determine associations with mortality and presence of metastasis.
Results: PSA screening was more frequent among survivors (66.9%, n = 287) than among deceased (22.0%, n = 24; p < 0.001). Median PSA at diagnosis was higher in those who died (123 vs 16 ng/mL; p < 0.001). PSA > 100 ng/mL was associated with ~50% probability of metastatic disease, rising to >95% for PSA > 323 ng/mL. High-risk D'Amico classification was strongly associated with metastasis (RR 6.67) and mortality (OR 14.24, p < 0.001). Bone pain was the predominant presenting symptom in the deceased group (76.1%, n = 83) and showed a strong association with metastasis (RR 8.146).
Conclusions: PSA screening was strongly associated with improved survival outcomes. Elevated PSA levels, high risk D'Amico classification and the presence of bone pain were important predictors of metastasis and mortality. The need to strengthen early detection in our population is evident, given the high percentage of patients presenting at advanced stages.
{"title":"No screening, no life: Perspectives from a sociodemographic characterization of prostate cancer patients.","authors":"Lucas J Cortés, Germán Olaya, José S Cortés, Juan I Caicedo, Jorge A Flórez","doi":"10.1177/03915603251412607","DOIUrl":"https://doi.org/10.1177/03915603251412607","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is the most common solid neoplasm in men, with an increasing incidence. This study describes clinical and sociodemographic features and PSA levels, and evaluate their associations with stage, risk categories, metastasis, and mortality in a public tertiary hospital in southern Colombia.</p><p><strong>Methodology: </strong>The present retrospective cohort study included 590 patients diagnosed with prostate cancer between 2020 and 2023. Sociodemographic and clinical variables, PSA levels, pathological characteristics and risk scales were analyzed. Patients were categorized into two groups: living (<i>n</i> = 429) and deceased by prostate cancer (<i>n</i> = 109), and other causes (<i>n</i> = 44). Statistical analyses were performed to determine associations with mortality and presence of metastasis.</p><p><strong>Results: </strong>PSA screening was more frequent among survivors (66.9%, <i>n</i> = 287) than among deceased (22.0%, <i>n</i> = 24; <i>p</i> < 0.001). Median PSA at diagnosis was higher in those who died (123 vs 16 ng/mL; <i>p</i> < 0.001). PSA > 100 ng/mL was associated with ~50% probability of metastatic disease, rising to >95% for PSA > 323 ng/mL. High-risk D'Amico classification was strongly associated with metastasis (RR 6.67) and mortality (OR 14.24, <i>p</i> < 0.001). Bone pain was the predominant presenting symptom in the deceased group (76.1%, <i>n</i> = 83) and showed a strong association with metastasis (RR 8.146).</p><p><strong>Conclusions: </strong>PSA screening was strongly associated with improved survival outcomes. Elevated PSA levels, high risk D'Amico classification and the presence of bone pain were important predictors of metastasis and mortality. The need to strengthen early detection in our population is evident, given the high percentage of patients presenting at advanced stages.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251412607"},"PeriodicalIF":0.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: We aim to present a peculiar case of a patient we treated, who underwent surgical excision of what at first were HPV-related condylomas of the urethral meatus. The second time he underwent surgical excision of what seemed a recurrence the histology showed a low grade noninvasive papillary urothelial carcinoma.
Case description: A 56-year-old man who underwent surgical excision of multiple lesions of the gland and distal urethra in April 2023; the histological examination of the neoformations in distal urethra confirmed the presence of condyloma acuminatum. He experienced a recurrence of distal urethral lesion; therefore, he underwent to a new surgical excision in September 2023 and this time the histological examination showed a transitional cell carcinoma.
Conclusion: There is still no clear evidence of the link between HPV infection and TCC, however attention must be placed in order to enhance awareness on HPV infection prevention and on TCC screening for patient with other HPV infection related diseases.
{"title":"Transitional cell carcinoma in distal urethra after previous excision of HPV related condyloma: Is there a link between human papilloma virus (HPV) and transitional cell carcinoma (TCC)?","authors":"Aldo Franco De Rose, Tommaso Saccucci, Benedetta Col, Fabrizio Gallo, Maurizio Chiaramondia, Guglielmo Mantica","doi":"10.1177/03915603251412604","DOIUrl":"https://doi.org/10.1177/03915603251412604","url":null,"abstract":"<p><strong>Introduction: </strong>We aim to present a peculiar case of a patient we treated, who underwent surgical excision of what at first were HPV-related condylomas of the urethral meatus. The second time he underwent surgical excision of what seemed a recurrence the histology showed a low grade noninvasive papillary urothelial carcinoma.</p><p><strong>Case description: </strong>A 56-year-old man who underwent surgical excision of multiple lesions of the gland and distal urethra in April 2023; the histological examination of the neoformations in distal urethra confirmed the presence of condyloma acuminatum. He experienced a recurrence of distal urethral lesion; therefore, he underwent to a new surgical excision in September 2023 and this time the histological examination showed a transitional cell carcinoma.</p><p><strong>Conclusion: </strong>There is still no clear evidence of the link between HPV infection and TCC, however attention must be placed in order to enhance awareness on HPV infection prevention and on TCC screening for patient with other HPV infection related diseases.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251412604"},"PeriodicalIF":0.7,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1177/03915603251408298
Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai
In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano®)-including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract-has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano® on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano® one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL (p < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano® may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.
{"title":"Prostate health supporting by a novel nutraceutical compound with antioxidant property: Results from a pilot study.","authors":"Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai","doi":"10.1177/03915603251408298","DOIUrl":"https://doi.org/10.1177/03915603251408298","url":null,"abstract":"<p><p>In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano<sup>®</sup>)-including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract-has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano<sup>®</sup> on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano<sup>®</sup> one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL (<i>p</i> < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano<sup>®</sup> may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251408298"},"PeriodicalIF":0.7,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: An intact vescio-ureteric junction (VUJ) complex is necessary to maintain its normal physiological function. A ureteric jet is produced when urine is vigorously propelled from the VUJ into the urinary bladder. The transplanted ureter lacks a normal VUJ but maintains its intrinsic peristaltic activity. this study was conducted to compare prospectively between the ureteric jet parameters in voluntary kidney donors by Doppler ultrasound of the same with patients who underwent ureteric re-implantation during a kidney transplantation procedure.
Methods: There were a total of 44 participants in the study. The outcome measurements were taken of the anteriorposterior diameter of the renal pelvis (RP-APD), the resistive index of the renal artery (RA-Ri), and ureteric jet parameters- the jet's maximum velocity, pattern, initial slope, direction, and duration. The patterns were of the following types - triphasic, biphasic, polyphasic, square, continuous, and monophasic.
Result: The biphasic and monophasic jet pattern was most common in the donor and recipient groups, respectively.
Conclusion: The Doppler waveform observed in transplanted ureters significantly differs from that seen in healthy voluntary kidney donors. This observation lends support to the theory that the native VUJ functions as a sphincter.
{"title":"Study of ureteric jet in kidney transplant recipient.","authors":"Sunil Kumar Das, VedVyas Mishra, Elisha Paikray, Bipin Bihari Pradhan","doi":"10.1177/03915603251410689","DOIUrl":"https://doi.org/10.1177/03915603251410689","url":null,"abstract":"<p><strong>Introduction: </strong>An intact vescio-ureteric junction (VUJ) complex is necessary to maintain its normal physiological function. A ureteric jet is produced when urine is vigorously propelled from the VUJ into the urinary bladder. The transplanted ureter lacks a normal VUJ but maintains its intrinsic peristaltic activity. this study was conducted to compare prospectively between the ureteric jet parameters in voluntary kidney donors by Doppler ultrasound of the same with patients who underwent ureteric re-implantation during a kidney transplantation procedure.</p><p><strong>Methods: </strong>There were a total of 44 participants in the study. The outcome measurements were taken of the anteriorposterior diameter of the renal pelvis (RP-APD), the resistive index of the renal artery (RA-Ri), and ureteric jet parameters- the jet's maximum velocity, pattern, initial slope, direction, and duration. The patterns were of the following types - triphasic, biphasic, polyphasic, square, continuous, and monophasic.</p><p><strong>Result: </strong>The biphasic and monophasic jet pattern was most common in the donor and recipient groups, respectively.</p><p><strong>Conclusion: </strong>The Doppler waveform observed in transplanted ureters significantly differs from that seen in healthy voluntary kidney donors. This observation lends support to the theory that the native VUJ functions as a sphincter.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251410689"},"PeriodicalIF":0.7,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-27DOI: 10.1177/03915603251406813
Hakan Şığva, Arif Mehmet Duran, Berat Deniz, Kadir Körpe, Mehmet Sevim
Purpose: This study aimed to develop and validate an AI-assisted framework for the automated evaluation of uroflowmetry data in patients presenting with lower urinary tract symptoms. The primary goal was to overcome the limitations of traditional manual interpretations by leveraging advanced machine learning techniques to achieve higher diagnostic accuracy, objectivity, and clinical applicability in urological assessments.
Materials and methods: A retrospective analysis was conducted using a large, de-identified dataset comprising uroflowmetry recordings, patient-reported symptom scores, and comprehensive demographic data. The data underwent rigorous preprocessing-including noise reduction, baseline correction, normalization, and feature extraction-with key parameters such as peak flow rate, voided volume, average flow rate, and voiding time being analyzed. Multiple machine learning models-including a deep neural network, support vector machine, and random forest classifier-were developed and validated through cross-validation and extensive statistical testing. Performance metrics such as accuracy, sensitivity, specificity, and area under the ROC curve (AUC-ROC) were calculated, while multivariate regression analyses were performed to explore the relationships between uroflowmetry parameters and symptom severity.
Results: The AI framework, particularly the deep neural network model, exhibited outstanding diagnostic performance with an accuracy of 92.5%, sensitivity of 90.0%, specificity of 94.0%, and an AUC-ROC of 0.96. Statistical analyses demonstrated significant correlations between key uroflowmetry parameters and clinical symptoms, with lower peak flow rates showing a strong association with increased symptom severity (p < 0.001). These findings confirm that the integration of multi-dimensional data through AI significantly enhances the objectivity and precision of urinary function evaluation compared to conventional methods.
Conclusion: The study successfully established an AI-assisted diagnostic framework that markedly improves the automated evaluation of uroflowmetry data and lower urinary tract symptoms. This innovative approach offers a robust alternative to traditional diagnostic practices by reducing subjectivity and enhancing diagnostic accuracy, thereby paving the way for more personalized and effective management of urinary disorders.
{"title":"Artificial intelligence-assisted uroflowmetry and automated evaluation of lower urinary system symptoms.","authors":"Hakan Şığva, Arif Mehmet Duran, Berat Deniz, Kadir Körpe, Mehmet Sevim","doi":"10.1177/03915603251406813","DOIUrl":"https://doi.org/10.1177/03915603251406813","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop and validate an AI-assisted framework for the automated evaluation of uroflowmetry data in patients presenting with lower urinary tract symptoms. The primary goal was to overcome the limitations of traditional manual interpretations by leveraging advanced machine learning techniques to achieve higher diagnostic accuracy, objectivity, and clinical applicability in urological assessments.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted using a large, de-identified dataset comprising uroflowmetry recordings, patient-reported symptom scores, and comprehensive demographic data. The data underwent rigorous preprocessing-including noise reduction, baseline correction, normalization, and feature extraction-with key parameters such as peak flow rate, voided volume, average flow rate, and voiding time being analyzed. Multiple machine learning models-including a deep neural network, support vector machine, and random forest classifier-were developed and validated through cross-validation and extensive statistical testing. Performance metrics such as accuracy, sensitivity, specificity, and area under the ROC curve (AUC-ROC) were calculated, while multivariate regression analyses were performed to explore the relationships between uroflowmetry parameters and symptom severity.</p><p><strong>Results: </strong>The AI framework, particularly the deep neural network model, exhibited outstanding diagnostic performance with an accuracy of 92.5%, sensitivity of 90.0%, specificity of 94.0%, and an AUC-ROC of 0.96. Statistical analyses demonstrated significant correlations between key uroflowmetry parameters and clinical symptoms, with lower peak flow rates showing a strong association with increased symptom severity (<i>p</i> < 0.001). These findings confirm that the integration of multi-dimensional data through AI significantly enhances the objectivity and precision of urinary function evaluation compared to conventional methods.</p><p><strong>Conclusion: </strong>The study successfully established an AI-assisted diagnostic framework that markedly improves the automated evaluation of uroflowmetry data and lower urinary tract symptoms. This innovative approach offers a robust alternative to traditional diagnostic practices by reducing subjectivity and enhancing diagnostic accuracy, thereby paving the way for more personalized and effective management of urinary disorders.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251406813"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robotic-Assisted Partial Nephrectomy (RAPN) can be performed via a transperitoneal (t-RAPN) or retroperitoneal (r-RAPN) approach. Despite the retroperitoneal route being potentially more suitable for posterior renal tumors, most surgeons prefer the transperitoneal access due to greater familiarity. This study evaluated perioperative and functional outcomes of r-RAPN versus t-RAPN for posterior renal masses performed by a surgeon without prior retroperitoneal experience. We retrospectively analyzed patients undergoing RAPN for posterior renal tumors between September 2023 and April 2025. Patient and tumor characteristics, operative time (OT), warm ischemia time (WIT), ΔeGFR, length of stay (LOS), complications, and Trifecta rate were compared. Trifecta was defined as WIT < 25 min, negative margins, and absence of Clavien-Dindo ⩾ III complications. Twenty patients were included: eight underwent t-RAPN and 12 r-RAPN. Baseline features were comparable. r-RAPN showed significantly shorter OT (125 ± 29 min vs 168 ± 37 min, p = 0.01), time on console (72 min vs 110 min, p = 0.01), and WIT (12 min vs 18 min, p = 0.048). Trifecta was achieved in all cases. Multivariate analysis identified surgical approach as the only independent predictor of console time (p = 0.024), with r-RAPN reducing it by 39 min. In conclusion, r-RAPN is feasible and safe even without prior retroperitoneal experience, offering comparable outcomes to t-RAPN with shorter operative times.
{"title":"Tailoring robotic-assisted partial nephrectomy: Should a retro- or transperitoneal approach be adapted based on tumor location, rather than surgeon's preference?","authors":"Valeria Feliciangeli, Nunzia Abbate, Luca Orecchia, Giuseppe Farullo, Anastasios Asimakopoulos, Enrico Finazzi Agrò, Simone Albisinni","doi":"10.1177/03915603251407024","DOIUrl":"https://doi.org/10.1177/03915603251407024","url":null,"abstract":"<p><p>Robotic-Assisted Partial Nephrectomy (RAPN) can be performed via a transperitoneal (t-RAPN) or retroperitoneal (r-RAPN) approach. Despite the retroperitoneal route being potentially more suitable for posterior renal tumors, most surgeons prefer the transperitoneal access due to greater familiarity. This study evaluated perioperative and functional outcomes of r-RAPN versus t-RAPN for posterior renal masses performed by a surgeon without prior retroperitoneal experience. We retrospectively analyzed patients undergoing RAPN for posterior renal tumors between September 2023 and April 2025. Patient and tumor characteristics, operative time (OT), warm ischemia time (WIT), ΔeGFR, length of stay (LOS), complications, and Trifecta rate were compared. Trifecta was defined as WIT < 25 min, negative margins, and absence of Clavien-Dindo ⩾ III complications. Twenty patients were included: eight underwent t-RAPN and 12 r-RAPN. Baseline features were comparable. r-RAPN showed significantly shorter OT (125 ± 29 min vs 168 ± 37 min, <i>p</i> = 0.01), time on console (72 min vs 110 min, <i>p</i> = 0.01), and WIT (12 min vs 18 min, <i>p</i> = 0.048). Trifecta was achieved in all cases. Multivariate analysis identified surgical approach as the only independent predictor of console time (<i>p</i> = 0.024), with r-RAPN reducing it by 39 min. In conclusion, r-RAPN is feasible and safe even without prior retroperitoneal experience, offering comparable outcomes to t-RAPN with shorter operative times.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251407024"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-27DOI: 10.1177/03915603251406809
Alberto Olivero, Sabrina De Cillis, Daniele Amparore, Sofia Giudici, Carlo Buratto, Valerio Cellini, Alberto Piana, Federico Piramide, Alberto Quarà, Cristian Fiori, Erika Palagonia, Paolo Dell'Oglio, Stefano Tappero, Aldo Massimo Bocciardi, Alberto Caviglia, Antonio Galfano, Bhaskar K Somani, Amelia Pietropaolo, Francesco Porpiglia, Silvia Secco
Background: In recent years, there has been a growing trend toward minimally-invasive techniques (MISTs) in men presenting symptomatic lower urinary tract symptoms (LUTS). However, direct comparisons between techniques are rare. This work compares 2-year functional outcomes and failure rates after implantable nitinol device (iTIND) and prostatic Urethral lift (Urolift).
Methods: Data of patients presenting with LUTS with an International Prostatic Symptom Score (IPSS) ⩾10, Qmax < 12 mL/s, and prostate volume < 70 mL were obtained retrospectively from two different referral centers' databases. Patients with neurogenic bladder, sphincter abnormalities, urethral strictures, post-void residual (PVR) volume > 250 mL, urinary bladder stones, and active urinary tract infections were excluded from the study. Treatment failure was defined as the need for surgical retreatment for LUTS or ejaculatory dysfunction. Postoperative uroflowmetry, PVR, IPSS, ejaculatory function, and retreatment rate were collected at 24 months follow-up.
Results: A total of 134 cases were collected. iTIND was used in 92 (68.7%) patients and Urolift in 42 (31.3%). Baseline characteristics were similar in both groups; however, Urolift patients were younger, with more significant prostate volumes and median lobe enlargement. No patients developed ejaculatory dysfunctions after the treatment, and the retreatment rate was similar in the two groups (13% vs 11.9% p = 0.8). Urolift demonstrated a shorter length of stay. Uroflowmetry, PVR volume, and symptom scores improved in both groups; iTIND cases showed significantly better symptom score reduction.
Conclusions: The 24-month failure rate was similar for iTIND and Urolift. Urolift reported a shorter hospitalization. Uroflowmetry and PVR results were comparable in both groups. iTIND cases showed slightly superior improvements in symptom scores; however, the clinical significance of this finding must be confirmed by further studies in correlation with prostate volume and median lobe shape.
背景:近年来,出现下尿路症状(LUTS)的男性越来越倾向于采用微创技术(mist)。然而,技术之间的直接比较很少。本研究比较了植入式镍钛诺装置(iTIND)和前列腺尿道提升(Urolift)术后2年的功能结局和失败率。方法:国际前列腺症状评分(IPSS)小于10,Qmax 250 mL,膀胱结石和活动性尿路感染的LUTS患者的数据被排除在研究之外。治疗失败被定义为需要手术治疗LUTS或射精功能障碍。随访24个月,收集术后尿流测量、PVR、IPSS、射精功能、复治率。结果:共收集病例134例。92例(68.7%)患者使用iTIND, 42例(31.3%)患者使用Urolift。两组的基线特征相似;然而,Urolift患者更年轻,前列腺体积和正中叶增大更明显。治疗后无患者出现射精功能障碍,两组再治疗率相似(13% vs 11.9% p = 0.8)。Urolift的停留时间较短。两组患者尿流测量、PVR容积和症状评分均有改善;iTIND病例表现出明显更好的症状评分降低。结论:iTIND和Urolift的24个月失败率相似。Urolift报告住院时间较短。两组尿流仪和PVR结果具有可比性。iTIND病例的症状评分略有改善;然而,这一发现的临床意义必须通过进一步研究前列腺体积和正中叶形状的相关性来证实。
{"title":"Twenty-four months failure rate and functional outcomes comparison after implantable nitinol device (iTIND) and prostatic urethral lift (Urolift): real world multicenter study.","authors":"Alberto Olivero, Sabrina De Cillis, Daniele Amparore, Sofia Giudici, Carlo Buratto, Valerio Cellini, Alberto Piana, Federico Piramide, Alberto Quarà, Cristian Fiori, Erika Palagonia, Paolo Dell'Oglio, Stefano Tappero, Aldo Massimo Bocciardi, Alberto Caviglia, Antonio Galfano, Bhaskar K Somani, Amelia Pietropaolo, Francesco Porpiglia, Silvia Secco","doi":"10.1177/03915603251406809","DOIUrl":"https://doi.org/10.1177/03915603251406809","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a growing trend toward minimally-invasive techniques (MISTs) in men presenting symptomatic lower urinary tract symptoms (LUTS). However, direct comparisons between techniques are rare. This work compares 2-year functional outcomes and failure rates after implantable nitinol device (iTIND) and prostatic Urethral lift (Urolift).</p><p><strong>Methods: </strong>Data of patients presenting with LUTS with an International Prostatic Symptom Score (IPSS) ⩾10, <i>Q</i>max < 12 mL/s, and prostate volume < 70 mL were obtained retrospectively from two different referral centers' databases. Patients with neurogenic bladder, sphincter abnormalities, urethral strictures, post-void residual (PVR) volume > 250 mL, urinary bladder stones, and active urinary tract infections were excluded from the study. Treatment failure was defined as the need for surgical retreatment for LUTS or ejaculatory dysfunction. Postoperative uroflowmetry, PVR, IPSS, ejaculatory function, and retreatment rate were collected at 24 months follow-up.</p><p><strong>Results: </strong>A total of 134 cases were collected. iTIND was used in 92 (68.7%) patients and Urolift in 42 (31.3%). Baseline characteristics were similar in both groups; however, Urolift patients were younger, with more significant prostate volumes and median lobe enlargement. No patients developed ejaculatory dysfunctions after the treatment, and the retreatment rate was similar in the two groups (13% vs 11.9% <i>p</i> = 0.8). Urolift demonstrated a shorter length of stay. Uroflowmetry, PVR volume, and symptom scores improved in both groups; iTIND cases showed significantly better symptom score reduction.</p><p><strong>Conclusions: </strong>The 24-month failure rate was similar for iTIND and Urolift. Urolift reported a shorter hospitalization. Uroflowmetry and PVR results were comparable in both groups. iTIND cases showed slightly superior improvements in symptom scores; however, the clinical significance of this finding must be confirmed by further studies in correlation with prostate volume and median lobe shape.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251406809"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1177/03915603251398255
Ahmed Issam Ali, Waseem Tayeb, Suhail A Kalantan, Abdelsalam Abdelfadel, Amr Talaat Azzam, Turky Almouhissen, Basem Othman, Abdullah Albkri, Abdulaziz Mohammed Bakhsh, Adel Moalwi, Ali Abdullah Alqahtani, Mohammed Kasem, Abdulrahim A Mirza, Ali Hassan
Purpose: This study presents a 1-year follow-up for fragile patients with catheter-dependent urinary retention related to benign prostatic hyperplasia (BPH) treated with Rezum therapy.
Materials and methods: All patients participating in this study exhibited catheter-dependent urine retention attributable to benign prostatic hyperplasia, with a mean prostate volume of 65 ± 13.1 ml. The study only included fragile patients with a PRISMA-7 questionnaire score of ⩾3. The study excluded patients with bladder or prostate cancer, ongoing urinary tract inflammation, a history of pelvic irradiation or prostate surgery, neurogenic bladder or urethral stricture. The treatment was carried out under local anesthesia, with the possibility of sedation. Patients were asked to follow up after 1, 2, 9, and 12 months of surgery. Clinical assessments included the IPSS score, bladder scans to determine pre- and post-voiding bladder volume, and an evaluation of the requirement for re-catheterization.
Results: Eighty fragile patients with PRISMA-7 score ⩾3 underwent Rezum treatment for urinary retention due to BPH. Patients were monitored for 1 year after the procedure. Patients' IPSS improved from 14 to 9.5 (p = 0.02), while post-void residual urine decreased from 50 mL to 12 mL (p < 0.001). Prostate volume reduced from 60.5 mL to 40.9 mL (p = 0.0003) and PSA levels also dropped, from 3.5 mg/dl to 2.3 ng/ml (p = 0.03).
Conclusion: This study demonstrates that Rezum therapy is a feasible treatment option for frail patients with PRISMA-7 questionnaire score of ⩾3, presented with catheter dependent urinary retention. There were reported positive post-operative outcomes and an improvement in IPSS scores up to one year after surgery.
目的:本研究对接受Rezum治疗的脆弱的导管依赖性尿潴留患者进行了为期1年的随访。材料和方法:所有参与本研究的患者均出现由良性前列腺增生引起的导管依赖性尿潴留,平均前列腺体积为65±13.1 ml。该研究仅包括PRISMA-7问卷评分为大于或等于3的脆弱患者。该研究排除了患有膀胱癌或前列腺癌、持续的尿路炎症、盆腔照射或前列腺手术史、神经源性膀胱或尿道狭窄的患者。治疗在局部麻醉下进行,可能有镇静作用。患者在手术1、2、9和12个月后被要求随访。临床评估包括IPSS评分,膀胱扫描以确定排尿前和排尿后的膀胱容量,以及对重新导尿需求的评估。结果:80名PRISMA-7评分大于或3的脆弱患者因BPH引起的尿潴留接受了Rezum治疗。术后随访1年。患者的IPSS从14改善到9.5 (p = 0.02),空后残尿从50 mL减少到12 mL (p = 0.0003), PSA水平也从3.5 mg/dl下降到2.3 ng/ mL (p = 0.03)。结论:本研究表明,对于PRISMA-7问卷评分大于或3的虚弱患者,出现导管依赖性尿潴留,Rezum治疗是一种可行的治疗选择。据报道,术后结果积极,IPSS评分在术后一年有所改善。
{"title":"Rezum therapy for management of frail patients with catheter dependent urinary retention due to benign prostate hyperplasia : A 1 year follow up study.","authors":"Ahmed Issam Ali, Waseem Tayeb, Suhail A Kalantan, Abdelsalam Abdelfadel, Amr Talaat Azzam, Turky Almouhissen, Basem Othman, Abdullah Albkri, Abdulaziz Mohammed Bakhsh, Adel Moalwi, Ali Abdullah Alqahtani, Mohammed Kasem, Abdulrahim A Mirza, Ali Hassan","doi":"10.1177/03915603251398255","DOIUrl":"https://doi.org/10.1177/03915603251398255","url":null,"abstract":"<p><strong>Purpose: </strong>This study presents a 1-year follow-up for fragile patients with catheter-dependent urinary retention related to benign prostatic hyperplasia (BPH) treated with Rezum therapy.</p><p><strong>Materials and methods: </strong>All patients participating in this study exhibited catheter-dependent urine retention attributable to benign prostatic hyperplasia, with a mean prostate volume of 65 ± 13.1 ml. The study only included fragile patients with a PRISMA-7 questionnaire score of ⩾3. The study excluded patients with bladder or prostate cancer, ongoing urinary tract inflammation, a history of pelvic irradiation or prostate surgery, neurogenic bladder or urethral stricture. The treatment was carried out under local anesthesia, with the possibility of sedation. Patients were asked to follow up after 1, 2, 9, and 12 months of surgery. Clinical assessments included the IPSS score, bladder scans to determine pre- and post-voiding bladder volume, and an evaluation of the requirement for re-catheterization.</p><p><strong>Results: </strong>Eighty fragile patients with PRISMA-7 score ⩾3 underwent Rezum treatment for urinary retention due to BPH. Patients were monitored for 1 year after the procedure. Patients' IPSS improved from 14 to 9.5 (<i>p</i> = 0.02), while post-void residual urine decreased from 50 mL to 12 mL (<i>p</i> < 0.001). Prostate volume reduced from 60.5 mL to 40.9 mL (<i>p</i> = 0.0003) and PSA levels also dropped, from 3.5 mg/dl to 2.3 ng/ml (<i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>This study demonstrates that Rezum therapy is a feasible treatment option for frail patients with PRISMA-7 questionnaire score of ⩾3, presented with catheter dependent urinary retention. There were reported positive post-operative outcomes and an improvement in IPSS scores up to one year after surgery.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251398255"},"PeriodicalIF":0.7,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1177/03915603251360159
Souvik Chatterjee, Smita Verma, Debansu Sarkar
Introduction: Urethral stricture is common in men with anterior being more common. Number of surgical techniques are there for anterior urethral stricture depending upon location and extent of stricture. To compare one technique with another in terms of complexity, intra-op difficulty and recurrence, no standard scoring system is there. In order to quantify anterior urethral stricture disease, Weigand developed USS (UREThRAL Stricture Score) in 2012. This scoring system was based on preoperative imaging and intraoperative findings. This scoring system has not been accepted worldwide. The aim of this study is to evaluate the USS in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture disease.
Methods: This ambidirectional study included patients operated for anterior urethral stricture in our institute. USS score for each patient was calculated preoperatively. Patients underwent optical internal urethrotomy (OIU), anastomotic urethroplasty or buccal mucosal graft urethroplasty (BMG). Complexity of surgery (in terms of duration of surgery and need of blood transfusion) and postoperative outcome (post op complications and recurrence) was evaluated for association with USS score.
Results: The study included 100 patients. Mean duration of surgery for overall study population was 99.39 ± 55.78 min with strong positive correlation of 0.76 (p-value < 0.001) with USS. Subgroup analysis revealed significant association between USS and postoperative complications (p-value 0.032) and recurrence of stricture (p-value 0.003) in OIU patients. There was also showed that there was significant association between USS and time to recurrence in patients who underwent OIU (p-value 0.007).
Conclusion: Our study validates the USS in predicting complexity of surgery, postoperative complications and recurrence in anterior urethral stricture disease. Higher the USS, more complex is the surgery needed for anterior urethral stricture, more chances of postoperative complications and recurrence of stricture.
{"title":"Evaluation of urethral stricture score (USS) in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture: An observational study.","authors":"Souvik Chatterjee, Smita Verma, Debansu Sarkar","doi":"10.1177/03915603251360159","DOIUrl":"https://doi.org/10.1177/03915603251360159","url":null,"abstract":"<p><strong>Introduction: </strong>Urethral stricture is common in men with anterior being more common. Number of surgical techniques are there for anterior urethral stricture depending upon location and extent of stricture. To compare one technique with another in terms of complexity, intra-op difficulty and recurrence, no standard scoring system is there. In order to quantify anterior urethral stricture disease, Weigand developed USS (UREThRAL Stricture Score) in 2012. This scoring system was based on preoperative imaging and intraoperative findings. This scoring system has not been accepted worldwide. The aim of this study is to evaluate the USS in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture disease.</p><p><strong>Methods: </strong>This ambidirectional study included patients operated for anterior urethral stricture in our institute. USS score for each patient was calculated preoperatively. Patients underwent optical internal urethrotomy (OIU), anastomotic urethroplasty or buccal mucosal graft urethroplasty (BMG). Complexity of surgery (in terms of duration of surgery and need of blood transfusion) and postoperative outcome (post op complications and recurrence) was evaluated for association with USS score.</p><p><strong>Results: </strong>The study included 100 patients. Mean duration of surgery for overall study population was 99.39 ± 55.78 min with strong positive correlation of 0.76 (<i>p</i>-value < 0.001) with USS. Subgroup analysis revealed significant association between USS and postoperative complications (<i>p</i>-value 0.032) and recurrence of stricture (<i>p</i>-value 0.003) in OIU patients. There was also showed that there was significant association between USS and time to recurrence in patients who underwent OIU (<i>p</i>-value 0.007).</p><p><strong>Conclusion: </strong>Our study validates the USS in predicting complexity of surgery, postoperative complications and recurrence in anterior urethral stricture disease. Higher the USS, more complex is the surgery needed for anterior urethral stricture, more chances of postoperative complications and recurrence of stricture.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251360159"},"PeriodicalIF":0.7,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}